Immunovaccine Seals Worldwide License Agreement With Pfizer Animal Health

Immunovaccine has entered into an exclusive, worldwide license agreement with Pfizer Animal Health for Immunovaccine’s patented vaccine delivery technology. Pfizer Animal Health has plans to develop enhanced cattle vaccines incorporating Immunovaccine’s technology.

As per the terms of the agreement, which were not disclosed, Immunovaccine is expected to receive upfront signing fees in addition to subsequent milestone payments and royalties on any Immunovaccine-delivered vaccines developed by Pfizer Animal Health.

Randal Chase, president and CEO of Immunovaccine, said: “Pfizer Animal Health is known around the world for its treatment and prevention of disease in cattle, and we are pleased to secure a further licensing agreement designed to advance their development of promising vaccines for veterinarians and producers. This is further validation of the commercial potential of our technology.”

Juan Ramon Alaix, president of Pfizer Animal Health, said: “We see global demand growing among beef and dairy producers for new vaccines that can be safely and easily administered. Pfizer looks forward to developing cattle vaccines incorporating Immunovaccine technology that will contribute to meeting this demand.”